Related coverage linked through entity extraction aliases.
Jul 07, 2026
AstraZeneca published a large-scale CNV analysis in Nature and partnered with Helix for clinico-genomic data. Quotient Therapeutics is using somatic genomics to identify disease-relevant mutations.
Jul 13, 2026
Cue Biopharma appointed Dominic Borie as chief medical officer and R&D head as it advances CUE-221 (Phase 2 data expected Q3 2026) and CUE-401 (Phase 1 start Q4 2026). He brings over 20 years of immunology and clinical development experience. The company recently raised $50M to support clinical development.
May 12, 2026
Two studies examined blood biomarkers for omalizumab response in chronic spontaneous urticaria. Basophil histamine content did not predict response, while higher baseline monocyte counts were linked to complete remission in a 52-patient retrospective analysis.
Apr 28, 2026
Novartis received EU approval for Rhapsido (remibrutinib) as the first oral targeted treatment for chronic spontaneous urticaria. Phase 3 data also showed significant efficacy in chronic inducible urticaria, with filings underway for additional indications.
Apr 14, 2026
A study in the Journal of Experimental Medicine found that DOCK8 deficiency drives severe food allergies by expanding Tfh13 cells and reducing regulatory T-cells. The findings help explain why DOCK8 mutations, but not STAT3 mutations alone, consistently lead to elevated food-specific IgE and clinically significant reactions.
